Fractyl Health Demonstrated That a Single Dose of a GLP-1-Based Pancreatic Gene Therapy Candidate (GLP-1 PGTx) Durably Maintained Weight Loss After Semaglutide Withdrawal in a Murine Model of Obesity at WCIRDC 2023 Annual Meeting Fractyl Health presented preclinical findings from its Rejuva® gene therapy platform at the WCIRD23 Annual Meeting.

Nemaura Includes Insulin on List of Drugs Eligible for EU DuoPack License Agreement LOUGHBOROUGH, March 15, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing...

Happy Bob Integrates With Dexcom CGM to Provide a Playful Way to Engage With Real-Time Glucose Values and Improve Overall Self-Care HELSINKI, March 08, 2022 (GLOBE NEWSWIRE) -- Diabetes tech startup Harald AI today introduced a more expansive way for Dexcom Continuous Glucose Monitoring (CGM) System users to engage with their...